Abstract
Thrombolytic therapy kick-started the era of modern cardiology but in the last few decades it has been largely supplanted by primary percutaneous coronary intervention (PCI) as the go-to treatment for acute myocardial infarction. However, these agents remain important for vast populations without access to primary PCI and acute ischemic stroke. More innovative uses have recently come up for the treatment of a variety of conditions. This article summarizes the history, evidence base and current use of thrombolytics in cardiovascular disease.
Keywords: Thrombolysis, acute myocardial infarction, catheter directed thrombolysis, pulmonary embolism, acute ischemic stroke, thrombolytic therapy.
Current Pharmaceutical Design
Title:Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond
Volume: 24 Issue: 4
Author(s): Patrick Proctor, Massoud A. Leesar and Arka Chatterjee*
Affiliation:
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL,United States
Keywords: Thrombolysis, acute myocardial infarction, catheter directed thrombolysis, pulmonary embolism, acute ischemic stroke, thrombolytic therapy.
Abstract: Thrombolytic therapy kick-started the era of modern cardiology but in the last few decades it has been largely supplanted by primary percutaneous coronary intervention (PCI) as the go-to treatment for acute myocardial infarction. However, these agents remain important for vast populations without access to primary PCI and acute ischemic stroke. More innovative uses have recently come up for the treatment of a variety of conditions. This article summarizes the history, evidence base and current use of thrombolytics in cardiovascular disease.
Export Options
About this article
Cite this article as:
Proctor Patrick , Leesar A. Massoud and Chatterjee Arka *, Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666171227211623
DOI https://dx.doi.org/10.2174/1381612824666171227211623 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside
Current Drug Targets Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges
Current Drug Metabolism Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery
Current Vascular Pharmacology Pharmacogenetics of Oral Anticoagulant Therapy
Current Pharmaceutical Design New Oral Anticoagulants and Their Reversal
Current Drug Safety Ximelagatran - A Promising New Drug in Thromboembolic Disorders
Current Pharmaceutical Design Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Current Signal Transduction Therapy Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Regulatory Considerations for Generic or Biosimilar Low Molecular Weight Heparins
Current Drug Discovery Technologies Cyano Acrylate Polymers in Medical Applications
Recent Patents on Materials Science The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design miR-29c-3p is an Effective Biomarker of Abdominal Aortic Aneurysm in Patients Undergoing Elective Surgery
MicroRNA Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Microvascular Thrombosis: An Exciting but Elusive Therapeutic Target in Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Non-transfusion Dependent Thalassemias: A Developing Country Perspective
Current Pediatric Reviews Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry